Tecnimede Group - Pharmaceutical Company

tecnimede.com

TECNIMEDE GROUP is composed by pharmaceutical companies of private and 100% Portuguese capital. Started its activity in 1980 and covers the entire life cycle of the medicinal products for human use: development, manufacture, promotion and marketing. TECNIMEDE GROUP's strategy is based on a strong investment in Research, Development and Production of Medicinal Products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

news image

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More

Views and Analysis

CHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR CHILDREN AGED 6 TO 11 YEARS WITH SEVERE ASTHMA WITH TYPE 2 INFLAMMATION

Regeneron Pharmaceuticals, Inc | January 31, 2022

news image

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequate...

Read More

Business Insights, PHARMACY MARKET

VERISTAT ACQUIRES EUROPEAN MEDICAL WRITING CONSULTANCY SCINOPSIS

Businesswire | June 13, 2023

news image

Veristat, a scientific-minded global clinical research organization (CRO), has acquired Scinopsis, a European medical writing consultancy with a 17-year track record of delivering regulatory and medical communication documents of the highest quality to the biopharmaceutical industry. The acquisition strengthens Veristat’s ability to meet growing client demand in one of its highest-valued service areas as the range of clinical trial content expands and the importance of regulatory doc...

Read More

Business Insights, PHARMA TECH

ALLIANCERX WALGREENS PHARMACY LAUNCHES RIGHTGUIDE TO HELP MINIMIZE TREATMENT BARRIERS

Prnewswire | April 27, 2023

news image

AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies in the country, is taking another step in developing innovative solutions with its recent launch of RightGuide, a custom digital engagement program that allows pharmaceutical manufacturers to seamlessly deliver educational support to patients living with rare diseases or chronic conditions. "RightGuide helps minimize potential treatment barriers, from training patients to self-administe...

Read More
news image

Business Insights

XERIS PHARMACEUTICALS STRENGTHENS ITS PATENT ESTATE

XERIS PHARMACEUTICALS, INC. | August 20, 2021

Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to ...

Read More
news image

Views and Analysis

CHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR CHILDREN AGED 6 TO 11 YEARS WITH SEVERE ASTHMA WITH TYPE 2 INFLAMMATION

Regeneron Pharmaceuticals, Inc | January 31, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequate...

Read More
news image

Business Insights, PHARMACY MARKET

VERISTAT ACQUIRES EUROPEAN MEDICAL WRITING CONSULTANCY SCINOPSIS

Businesswire | June 13, 2023

Veristat, a scientific-minded global clinical research organization (CRO), has acquired Scinopsis, a European medical writing consultancy with a 17-year track record of delivering regulatory and medical communication documents of the highest quality to the biopharmaceutical industry. The acquisition strengthens Veristat’s ability to meet growing client demand in one of its highest-valued service areas as the range of clinical trial content expands and the importance of regulatory doc...

Read More
news image

Business Insights, PHARMA TECH

ALLIANCERX WALGREENS PHARMACY LAUNCHES RIGHTGUIDE TO HELP MINIMIZE TREATMENT BARRIERS

Prnewswire | April 27, 2023

AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies in the country, is taking another step in developing innovative solutions with its recent launch of RightGuide, a custom digital engagement program that allows pharmaceutical manufacturers to seamlessly deliver educational support to patients living with rare diseases or chronic conditions. "RightGuide helps minimize potential treatment barriers, from training patients to self-administe...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us